Dr. Ardis warns remdesivir dangers, demands urgent oversight.

Claims an Ebola trial funded by Anthony Fauci showed remdesivir had a 40–54% mortality rate and was removed from the study for safety concerns.

Alleges that six months after the study was published, Fauci recommended remdesivir as the primary COVID-19 treatment for all U.S. hospitals.

States the U.S. was the only country in 2020 that purchased the entire supply of remdesivir for exclusive national use.

Suggests this widespread use in American ICUs contributed to higher COVID-19 mortality in the U.S.

Cites an April 2021 WHO safety database review and claims it showed disproportionately high reports of acute renal failure linked to remdesivir—allegedly 20 times higher than comparison drugs.

Describes acute renal failure as kidney shutdown leading to severe fluid retention, potential heart sac saturation, lung flooding, and fatal outcomes.

Notes that hydroxychloroquine was previously studied for SARS-CoV-1 and suggests it showed early promise.